利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.069 秒)

    TIME-SELECTIVE BIORESORBABLE OR COLLAPSIBLE DRUG DELIVERY SYSTEMS AND METHODS
    4.
    发明申请
    TIME-SELECTIVE BIORESORBABLE OR COLLAPSIBLE DRUG DELIVERY SYSTEMS AND METHODS 有权
    时间选择性生物可降解或可溶性药物递送系统和方法

    公开(公告)号：US20120089122A1

    公开(公告)日：2012-04-12

    申请号：US13267560

    申请日：2011-10-06

    申请人： Heejin Lee ,  Michael J. Cima ,  Cheryl Larrivee-Elkins ,  Dennis Geising ,  Jessica K. Anderson ,  Sarma Duddu

    发明人： Heejin Lee ,  Michael J. Cima ,  Cheryl Larrivee-Elkins ,  Dennis Geising ,  Jessica K. Anderson ,  Sarma Duddu

    IPC分类号： A61M25/00

    CPC分类号： A61M31/002 ,  A61K9/0034 ,  A61K9/0039 ,  A61L29/148 ,  A61L29/16 ,  A61L31/148 ,  A61L31/16 ,  A61L2300/00

    摘要： Implantable medical devices and treatment methods are provided, particularly for use in the bladder. The device is configured for retention in the bladder for at least a portion of the drug delivery period and includes at least one biodegradable component such that following a biodegradation at a selected time, the retention function is lost and the device or portions thereof are resorbed and/or excreted. The method may include deploying into the bladder of a patient a device having a device structure housing a drug formulation comprising at a drug; releasing drug from the device structure into the bladder; and then, changing the composition of urine in the bladder, e.g., by altering the pH, to trigger degradation of at least part of the device structure to enable the device structure or parts thereof to be excreted from the bladder.

    摘要翻译： 提供了可植入的医疗装置和治疗方法，特别用于膀胱。 该装置构造成在膀胱中保留药物递送期的至少一部分，并且包括至少一种可生物降解的组分，使得在选定时间内经过生物降解后，保留功能丧失并且其装置或部分被吸收， /或排泄。 该方法可以包括向患者的膀胱中部署具有容纳包含药物的药物制剂的装置结构的装置; 将药物从装置结构释放到膀胱中; 然后，例如通过改变pH来改变膀胱中尿液的组成，以触发装置结构的至少一部分的降解，使装置结构或其部分能够从膀胱排出。

    Time-selective bioresorbable or collapsible drug delivery systems and methods
    5.
    发明授权
    Time-selective bioresorbable or collapsible drug delivery systems and methods 有权
    时间选择性生物可吸收或可折叠药物递送系统和方法

    公开(公告)号：US08690840B2

    公开(公告)日：2014-04-08

    申请号：US13267560

    申请日：2011-10-06

    申请人： Heejin Lee ,  Michael J. Cima ,  Cheryl Larrivee-Elkins ,  Dennis Giesing ,  Jessica K. Anderson ,  Sarma Duddu

    发明人： Heejin Lee ,  Michael J. Cima ,  Cheryl Larrivee-Elkins ,  Dennis Giesing ,  Jessica K. Anderson ,  Sarma Duddu

    IPC分类号： A61M31/00

    CPC分类号： A61M31/002 ,  A61K9/0034 ,  A61K9/0039 ,  A61L29/148 ,  A61L29/16 ,  A61L31/148 ,  A61L31/16 ,  A61L2300/00

    摘要： Implantable medical devices and treatment methods are provided, particularly for use in the bladder. The device is configured for retention in the bladder for at least a portion of the drug delivery period and includes at least one biodegradable component such that following a biodegradation at a selected time, the retention function is lost and the device or portions thereof are resorbed and/or excreted. The method may include deploying into the bladder of a patient a device having a device structure housing a drug formulation comprising at a drug; releasing drug from the device structure into the bladder; and then, changing the composition of urine in the bladder, e.g., by altering the pH, to trigger degradation of at least part of the device structure to enable the device structure or parts thereof to be excreted from the bladder.

    摘要翻译： 提供了可植入的医疗装置和治疗方法，特别用于膀胱。 该装置构造成在膀胱中保留药物递送期的至少一部分，并且包括至少一种可生物降解的组分，使得在选定时间内经过生物降解后，保留功能丧失并且其装置或部分被吸收， /或排泄。 该方法可以包括向患者的膀胱中部署具有容纳包含药物的药物制剂的装置结构的装置; 将药物从装置结构释放到膀胱中; 然后，例如通过改变pH来改变膀胱中尿液的组成，以触发装置结构的至少一部分的降解，使装置结构或其部分能够从膀胱排出。

    Sustained release theophylline formulations, excipient systems and methods of production
    8.
    发明授权
    Sustained release theophylline formulations, excipient systems and methods of production 失效
    持续释放茶碱制剂，赋形剂体系和生产方法

    公开(公告)号：US06171615B2

    公开(公告)日：2001-01-09

    申请号：US09110599

    申请日：1998-07-06

    申请人： Pascale Roussin ,  Sarma Duddu

    发明人： Pascale Roussin ,  Sarma Duddu

    IPC分类号： A61K952

    CPC分类号： A61K31/522 ,  A61K9/4858 ,  A61K9/4866

    摘要： A stable sustained release theophylline formulation is prepared by incorporating theophylline into a semi-solid matrix comprising polyglycolized glycerides (GELUCIRE® excipient) and a mixture of nucleation enhancers. Theophylline is admixed with molten GELUCIRE to make the sustained release formulation. The nucleation enhancer composition is then incorporated in the admixture to make the sustained release formulation resistant to changes in dissolution upon aging. Orally administrable compositions are prepared by filling gelatin capsules with the formulation. The polyglycolized glycerides (GELUCIRE) and the nucleation enhancer composition also can be used as an excipient system for preparing sustained release pharmaceutical compositions.

    摘要翻译： 通过将茶碱掺入包含聚乙二醇化甘油酯（GELUCIRE）赋形剂的半固体基质）和成核增强剂的混合物来制备稳定的持续释放茶碱制剂。 将茶碱与熔融的GELUCIRE混合以制备缓释制剂。 然后将成核增强剂组合物掺入混合物中以使缓释制剂对老化时的溶解变化具有抗性。 通过用制剂填充明胶胶囊制备口服给药组合物。 聚乙二醇化甘油酯（GELUCIRE）和成核增强剂组合物也可用作制备缓释药物组合物的赋形剂体系。